Clinical trials: Pyoderma
Pyoderma Gangrenosum
Phase III Trial to Investigate Efficacy and Safety of Vilobelimab in Ulcerative Pyoderma Gangrenosum
A randomized, double-blind, placebo-controlled, multicenter, adaptive phase III trial to investigate efficacy and safety of vilobelimab in the treatment of ulcerative pyoderma gangrenosum
- Trial name
- NCT05964413
- Testing
- vilobelimab
- Where
- 50 sites in United States, Australia and 8 more
- Volunteers
- 54 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum, Skin Diseases
Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)
An Open-Label, Proof-Of-Concept, Study of Baricitinib for the Treatment of Pyoderma Gangrenosum
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma
- Trial name
- NCT04901325
- Testing
- Baricitinib
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum
A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan
This study is designed to investigate the efficacy, safety and pharmacokinetics of adalimumab in subjects in Japan with active ulcer(s) due to Pyoderma Gangrenosum (PG).
- Trial name
- NCT03311464
- Testing
- adalimumab
- Where
- 20 sites in Japan
- Volunteers
- 22 people
- Sponsor
- AbbVie
Pyoderma Gangrenosum, Skin Diseases
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma
- Trial name
- GEORGE (NCT06563323)
- Testing
- Guselkumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oregon Health and Science University
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Pyoderma Gangrenosum
Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum
The purpose of this research study is to find out what effects (good and bad) secukinumab has on the subject and their pyoderma gangrenosum. Secukinumab is a type of medicine called human monoclonal antibodies.
- Trial name
- NCT04274166
- Testing
- secukinumab 150 mg (2 injections per dose
- Sponsor
- Wake Forest University Health Sciences
Pyoderma Gangrenosum
Canakinumab for Pyoderma Gangrenosum
This study is a prospective open label evaluation of Canakinumab (Ilaris) for treatment of subjects with pyoderma gangrenosum.
- Trial name
- NCT01302795
- Testing
- Canakinumab
- Where
- Switzerland
- Volunteers
- 5 people
- Sponsor
- University of Zurich
Pyoderma Gangrenosum
Study on the Clinical Features, Comorbidities and Pathologies Associated With Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a rare disease. She is often under diagnosed and a source of diagnostic wandering and inadequate care.
- Trial name
- PYODERMA (NCT03636737)
- Testing
- pathology associated
- Where
- France
- Volunteers
- 140 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Pyoderma Gangrenosum
Exploratory Study of IFX-1 in Patients With Pyoderma Gangrenosum
The purpose of this study is to determine whether vilobelimab (development name: IFX-1) is safe and effective in the treatment of pyoderma gangrenosum.
- Trial name
- NCT03971643
- Testing
- vilobelimab
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 19 people
- Sponsor
- InflaRx GmbH
Pyoderma Gangrenosum
Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum
Rationale: Pyoderma gangrenosum (PG) is a rare auto-inflammatory neutrophilic dermatosis characterized by a spectrum of clinical presentations with variable courses. Diagnosis and management are challenging in PG.
- Trial name
- HOTPANTS (NCT05343754)
- Testing
- Hyperbaric oxygen, Control group
- Where
- Netherlands
- Volunteers
- 3 people
- Sponsor
- Erasmus Medical Center
Pyoderma Gangrenosum
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
This is a single-center, open-label, single-arm pilot study evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers.
- Trial name
- TRIUMPH (NCT07783412)
- Testing
- topical ruxolitinib 1.5% cream
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Oregon Health and Science University
Pyoderma
Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma
The study is aimed to: evaluate the effectiveness of 10-day therapy with Dioxidin® compared with Miramistin® in the treatment of superficial pyoderma, evaluate the safety and tolerability of 10-day therapy with Dioxidin® compared…
- Trial name
- NCT05561816
- Testing
- Hydroxymethylquinoxalindioxyde, Benzyl-dimethyl-[3-(tetradecanoylamino)propyl]azanium
- Where
- 10 sites in Russia
- Volunteers
- 240 people
- Sponsor
- Valenta Pharm JSC
Pyoderma Gangrenosum
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum
The purpose of this study is to determine if treatment with Xionix will improve wound healing for patients with pyoderma gangrenosum.
- Trial name
- NCT01965613
- Testing
- Xilonix
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Crohn Disease
Topical Tacrolimus 0.1% Ointment For Treatment Of Cutaneous Crohn's Disease
An assessment of the efficacy of topical tacrolimus in the treatment of cutaneous crohns disease
- Trial name
- NCT01233570
- Testing
- Tacrolimus
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- University of Aberdeen
Pyoderma Gangrenosum
An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum
The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).
- Trial name
- NCT02326740
- Testing
- gevokizumab, gevokizumab open-label
- Where
- 16 sites in United States, Australia and 1 more
- Volunteers
- 9 people
- Sponsor
- XOMA (US) LLC
Solid Tumors
A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors
The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.
- Trial name
- NCT03386942
- Testing
- Farletuzumab Ecteribulin
- Where
- 10 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Eisai Inc.
Pyoderma Gangrenosum
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
The purpose of this Phase 2a, open label, proof-of-concept clinical study is to assess the efficacy and safety of etrasimod (APD334) in patients with Pyoderma Gangrenosum.
- Trial name
- NCT03072953
- Testing
- APD334
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 2 people
- Sponsor
- Arena Pharmaceuticals
Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
This study investigates the genetic architecture of Neutrophil-Mediated Inflammatory Skin Diseases. After collecting informed consent, all patients' clinical phenotype is graded at inclusion with a detailed case report form and a…
- Conditions
- Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum, Erosive Pustular Dermatosis of the Scalp, Sweet's Syndrome
- Trial name
- NEUTROGENE (NCT01952275)
- Testing
- Collection of biological samples
- Where
- Switzerland
- Volunteers
- 600 people
- Sponsor
- University of Zurich
Pyoderma Gangrenosum
Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum
The purpose of this research study is to see if Humira (adalimumab) is effective and safe in the treatment of pyoderma gangrenosum.
- Trial name
- NCT00690846
- Testing
- adalimumab
- Where
- United States
- Sponsor
- Wake Forest University Health Sciences
Pyoderma Gangrenosum
Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum
Pyoderma gangrenosum (PG) is a chronic inflammatory condition with severe painful ulcers. We hypothesize that Platelet-rich plasma(PRP) therapy derived from patient's own blood has a high concentration of endogenous growth…
- Trial name
- NCT05984654
- Testing
- Platelet rich plasma therapy
- Where
- United States
- Sponsor
- Ohio State University